A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 2, 2005, Pages 109-113

  Artz, Andrew ^a   Stadler, Walter M ^a   Vogelzang, Nicholas J ^a   Zimmerman, Todd ^a   Ryan, Christopher ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Antineoplastic combined chemotherapy protocols; Carcinoma; Drug evaluation; Transitional cell

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; STEROID;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEHYDRATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EVALUATION; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; KIDNEY FAILURE; LIVER TOXICITY; LUNG EMBOLISM; LUNG INFILTRATE; MALE; METASTASIS; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; REFLUX ESOPHAGITIS; RESPIRATORY TRACT DISEASE; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KIDNEY NEOPLASMS; KIDNEY PELVIS; MALE; METHOTREXATE; MIDDLE AGED; SURVIVAL ANALYSIS; TAXOIDS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 17044404567     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000142591.62299.8f     Document Type: Article

References (23)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-3077.
3. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989;64:2448-2458.
4. Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 1994;12:2264-2270.
5. de Wit R, Kruit WH, Stoter G, et al. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer. 1998;78:1342-1345.
6. Roth BJ. Ifosfamide in the treatment of bladder cancer. Semin Oncol. 1996;23:50-55.
7. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep. 1986;70:163-169.
8. Maluf FC, Hilton S, Nanus D, et al. Sequential doxorubicin/gemcitabine (AG) and ifosfamide, paclitaxel, and cisplatin (ITP) chemotherapy in patients (pts) with metastatic or locally advanced transitional cell carcinoma of the urothelium (TCC). Proc Am Soc Clin Oncol. 2000.
9. Dodd PM, McCaffrey JA, Hilton S, et al. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol. 2000;18:840-846.
10. Williams D, Millikan R. Pilot study of sequentially applied doublets in poor-prognosis metastatic urothelial cancer. Urol Oncol. 2002;7:235-237.
11. Dimopoulos MA, Deliveliotis C, Moulopoulos LA, et al. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. Urology. 1998;52:56-60.
12. Stadler WM, Roth BJ. Chemotherapy for metastatic transitional cell cancer of the urothelial tract. In: Vogelzang NJ, Scardino PT, Shiplely WU, et al., eds. Comprenhensive Textbook of Genitourinary Oncology. Philadelphia: Lippincott Williams & Wilkins; 2000.
13. Droz JP, Zanetta S, Guillot A, et al. Clinical and pharmacokinetic (PK) results of a phase I trial of docetaxel (TXT) in combination with methotrexate (MTX) in patients (pts) with epithelial cancer. Proc Am Soc Clin Oncol. 1999:167a.
14. Brand R, Capadano M, Tempero M. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs. 1997;15:331-341.
15. Conaway M, Petroni G. Bivariate sequential designs for phase II trials. Biometrics. 1995;51:656-664.
16. Stata Statistical Software; 8.0 ed. College Station, TX: Stata Corp; 2003.
17. Louwerens M, Smorenburg C, Sparreboom A, et al. Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours. Eur J Cancer. 2002;38:497-504.
18. Smorenburg CH, Sparreboom A, Bontenbal M, et al. Combination chemotherapy of the taxanes and antimetabolites: its use and limitations. Eur J Cancer. 2001;37:2310-2323.
19. Tempero MA, Brand R. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1998;82:1800-1801.
20. Cannon GW. Methotrexate pulmonary toxicity. Rheum Dis Clin North Am. 1997;23:917-937.
21. Thomas AL, Cox G, Sharma RA, et al. Gemcitabine and paclitaxel associated pneumonia's in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer. 2000;36:2329-2334.
22. Bellmunt J, Cos J, Cleries R, et al. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest. 2002;20:673-685.
23. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173-3181.